Blast phase of essential thrombocythemia: A single center study

American Journal of Hematology

Volumn 84, Issue 10, 2009, Pages 641-644

  Passamonti, Francesco ^a   Rumi, Elisa ^a   Arcaini, Luca ^a   Elena, Chiara ^a   Castagnola, Carlo ^a   Zappasodi, Patrizia ^a   Bernasconi, Paolo ^a   Pietra, Daniela ^a   Pascutto, Cristiana ^a   Cazzola, Mario ^a   Lazzarino, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; FLUDARABINE; HEMOGLOBIN; IDARUBICIN; TIOGUANINE;

ACUTE LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; BLAST CELL CRISIS; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; COMORBIDITY; FEMALE; FOLLOW UP; GENE MUTATION; GRANULOCYTE; HUMAN; KARYOTYPE; LEUKOCYTOSIS; MALE; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STRATIFICATION; THROMBOCYTE COUNT; THROMBOCYTHEMIA;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BLOOD PLATELETS; DISEASE-FREE SURVIVAL; FEMALE; HEMOGLOBINS; HUMANS; JANUS KINASE 2; LEUKOCYTE COUNT; LEUKOCYTES; MALE; MIDDLE AGED; MUTATION; PLATELET COUNT; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL;

EID: 70349510611     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21496     Document Type: Article

References (42)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097. (Pubitemid 47281402)
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790. (Pubitemid 40570926)
3. Pietra D, Li S, Brisci A, et al. Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood 2008;111:1686-1689. (Pubitemid 351213460)
4. Pikman Y, Lee BH, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 2006;3:e270. (Pubitemid 44125998)
5. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia 2009;23:905-911.
6. Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: Clinical phenotype and evidence of disease anticipation. J Clin Oncol 2007;25:5630-5635.
7. Rumi E, Passamonti F, Picone C, et al. Disease anticipation in familial myeloproliferative neoplasms. Blood 2008;112:2587-2588; author reply 2588-2589.
8. Pardanani A. JAK2 inhibitor therapy in myeloproliferative disorders: Rationale, preclinical studies and ongoing clinical trials. Leukemia 2008;22:23-30.
9. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737-740.
10. Abdulkarim K, Girodon F, Johansson P, et al. AML transformation in 56 patients with Ph- MPD in two well defined populations. Eur J Haematol 2009;82:106-111.
11. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008;112:1628-1637.
12. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761. (Pubitemid 39482529)
13. Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: A single institutional study of 605 patients. Leukemia 2007;21:270-276. (Pubitemid 46158119)
14. Theocharides A, Boissinot M, Girodon F, et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007;110:375-379. (Pubitemid 47026857)
15. Campbell PJ, Baxter EJ, Beer PA, et al. Mutation of JAK2 in the myeloproliferative disorders: Timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Blood 2006;108:3548-3555.
16. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: A study of 605 patients. Haematologica 2008;93:1645-1651.
17. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583. (Pubitemid 30769256)
18. Cervantes F, Tassies D, Salgado C, et al. Acute transformation in nonleukemic chronic myeloproliferative disorders: Actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-127.
19. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998;92:2322-2333. (Pubitemid 28452973)
20. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990;66:549-556. (Pubitemid 20233455)
21. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 1998;91:616-622. (Pubitemid 28053386)
22. Bellucci S, Janvier M, Tobelem G, et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986;58:2440-2447.
23. Passamonti F, Brusamolino E, Lazzarino M, et al. Efficacy of pipobroman in the treatment of polycythemia vera: Long-term results in 163 patients. Haematologica 2000;85:1011-1018. (Pubitemid 30831931)
24. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670. (Pubitemid 40446255)
25. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008;112:1402-1412.
26. Reilly JT. Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). Leukemia 2008;22:1818-1827.
27. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, Nerlov C. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002;99:1909-1912. (Pubitemid 34525468)
28. Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: A single center study of 23 patients. Cancer 2005;104:1032-1036. (Pubitemid 41170231)
29. Hernandez JA, Florensa L, Sole F, et al. Acute myeloid leukemia with 17p abnormality in untreated essential thrombocythemia. Leukemia 2001;15:1308. (Pubitemid 32776460)
30. Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-1907.
31. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005;106:3370-3373.
32. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005;105:973-977.
33. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005;105:4115-4119. (Pubitemid 40656163)
34. Kroger N, Zabelina T, Schieder H, et al. Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis. Br J Haematol 2005;128:690-697. (Pubitemid 40343239)
35. Vardiman JW, Harris NL, Brunning RD. The world health organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-2302.
36. Bennett JM, Catovsky D, Dalniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British cooperative group. Ann Intern Med 1985;103:620-625.
37. Cheson BD, Cassileth PA, Head DR, et al. Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813-819.
38. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the polycythemia vera study group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39. (Pubitemid 27063140)
39. Silverstein MN. Primary or hemorrhagic thrombocythemia. Arch Intern Med 1968;122:18-22.
40. Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 2008;22:437-438. (Pubitemid 351250553)
41. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: Relations to morphology, clinical evolution, and survival. Am J Hematol 1994;46:270-277. (Pubitemid 24243869)
42. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood 2006;107:3676-3682.